High-Value Federal Grants ($5M+) — July 24, 2026

Leidos Holdings' subsidiary won a $173.3M cost-plus-fixed-fee delivery order for Phase 1/2 vaccine trials through 2029, with $36.8M already funded. The cost-plus structure minimizes profit volatility and provides steady annual revenue of ~$28.9M.

PTSI's firm-fixed-price contract with NASA Goddard is 78% outlayed ($102.1M) and ended in September 2023, creating a revenue gap risk unless new awards are secured. The company's dependency on this single contract is a concentration concern.

Frequentis USA secured a time-and-materials contract for APC units with $105.1M already outlayed, signaling high funding certainty. However, as a foreign-owned entity, it faces regulatory risk in the transportation sector.

Raytheon (RTX) received a non-competed, cost-plus-fixed-fee delivery order for aircraft ground handling equipment modification. The $28.3M annual revenue is immaterial for RTX ($69B+ revenue), but the sole-source award confirms its entrenched FAA relationship.

PTSI Managed Services faces high revenue concentration risk as its $130.8M NASA contract is 78% complete with no visible follow-on awards, creating a potential revenue cliff.

Frequentis USA, as a foreign-owned entity, faces elevated regulatory risk in the FAA's telecom equipment supply chain, which could impact contract renewals or future awards.

PTSI's firm-fixed-price contract transfers cost risk to the contractor, though the long performance period (2017-2023) suggests successful execution to date.

Leidos Biomedical's $173.3M NIH contract provides a stable, long-term revenue stream through 2029 with potential for expansion if vaccine trial outcomes are successful, leading to follow-on awards.

Raytheon's sole-source $113.2M FAA award under the STARS program indicates an entrenched incumbent position that could lead to additional non-competed task orders for air traffic control modernization.

Frequentis USA's $124.6M FAA contract for APC units and APCMS positions the company for follow-on work as the FAA continues modernizing air traffic control infrastructure through 2027.

Three of four contracts ($368.5M total) involve infrastructure or equipment modernization at NASA Goddard and the FAA, indicating sustained investment in physical and IT infrastructure by civilian agencies.

Leidos Biomedical's $173.3M NIH contract demonstrates the durability of health research funding, with cost-plus pricing reducing profit risk and long performance periods providing revenue visibility.

{"entity" => "Leidos Holdings Inc. (LDOS)", "reason" => "Holds the highest-value ($173.3M) and most durable contract in this digest, with cost-plus pricing and a 6-year performance period through 2029.", "trigger" => "Monitor future funding obligations under the NIH delivery order to assess if the full $173.3M is realized"}

{"entity" => "PTSI Managed Services Inc.", "reason" => "Faces a revenue cliff as its $130.8M NASA contract is nearly complete (78% outlayed) with no visible follow-on awards.", "trigger" => "Monitor for new NASA GSFC facility contracts awarded to PTSI after 2023"}

{"entity" => "Frequentis USA, Inc.", "reason" => "Holds a $124.6M FAA contract with high funding certainty ($105.1M outlayed) but faces foreign-ownership regulatory risk.", "trigger" => "Watch for any regulatory changes affecting foreign-owned transportation contractors"}

{"entity" => "RTX Corporation (RTX)", "reason" => "Sole-source $113.2M FAA award confirms incumbent position, but revenue is immaterial to overall business.", "trigger" => "Monitor for any modifications or follow-on awards under the STARS program"}